Cargando…

PB1903: THE PROGNOSTICATION FACTORS IN DE NOVO AML PATIENTS IN A SINGLE CENTER: DO THEY HAVE DIFFERENCES THAN THE REPORTED DATA?

Detalles Bibliográficos
Autor principal:	Ibrahim, Nahla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430359/ http://dx.doi.org/10.1097/01.HS9.0000974436.24264.77

Ejemplares similares

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB1804: CLINICAL AND DEMOGRAFIC RELATIONS OF BAALC GENE OVEREXPRESSION IN AML PATIENTS - A SINGLE-CENTER OBSERVATIONS
por: Aleksov, E., et al.
Publicado: (2022)

PB1882: BONE MARROW LYMPHOCYTES AND SUBPOPULATION: A NOVEL PROGNOSTIC INDICATOR IN ACUTE MYELOID LEUKEMIA
por: Ibrahim, Nahla
Publicado: (2023)

PB1800: CLINICAL CHARACTERISTICS AND MUTATION LANDSCAPE OF TRISOMY AML
por: Lam, Stephen S Y, et al.
Publicado: (2023)

PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16)
por: Bessmertniy, Dmitry, et al.
Publicado: (2023)

PB1896: ACUTE MYELOID LEUKEMIA (AML): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB2522: LIPID PROFILE AND CARDIAC FUNCTIONS IN EGYPTIAN SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER STUDY
por: El Ghamrawy, Mona, et al.
Publicado: (2023)

PB1797: THE PROGNOSTIC SIGNIFICANCE OF BCAT1 ON NPM1+FLT3-ITD+ AML PATIENTS AND RELATED MOLECULAR MECHANISMS
por: Pan, Xinan, et al.
Publicado: (2023)

PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB1946: ACQUIRED AMEGAKARYOCYTIC THROMBOCYTOPENA (AAMT), A SINGLE CENTER EXPERIENCE
por: Mohamed, S., et al.
Publicado: (2022)

PB1783: IDENTIFICATION OF RAMAN SPECTROSCOPIC SIGNATURE OF IDH MUTATIONS IN AML IN VITRO MODEL
por: Laskowska, P., et al.
Publicado: (2022)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

PB1770: CHARACTERIZATION OF THE MUTATIONAL PROFILE OF PATIENTS WITH CBF-AML - HETEROGENEITY AND IMPACT ON THE PROGNOSIS
por: Motyko, Ekaterina, et al.
Publicado: (2023)

PB1768: MICRORNA SIGNATURES IMPLY A ROLE FOR FOXO IN AML CHEMO-RESISTANCE
por: Reichelt, Paula, et al.
Publicado: (2023)

PB1863: VENETOCLAX AND HYPOMETHYLATING AGENT BASED OUTPATIENT AML INDUCTION- COST-EFFECTIVE METHOD FOR LMICS-REAL WORLD DATA FROM A TERTIARY CARE CENTER
por: Chauhan, Priyanka, et al.
Publicado: (2023)

PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE
por: Serin, I., et al.
Publicado: (2022)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

PB1787: PLZF-RARΑ ENHANCES METABOLIC PLASTICITY AND ROS SCAVENGING IN AML CELLS
por: Zaza, Alessandra, et al.
Publicado: (2023)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

PB1812: CO-MUTATION PROFILE IN A REAL-LIFE COHORT OF ACUTE MYELOID LEUKEMIA (AML)
por: Piras, Giovanna, et al.
Publicado: (2023)

PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hijiya, N., et al.
Publicado: (2022)

PB1852: COMPARISON OF CLINICAL CHARACTERISTICS OF ADULT CHILEAN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), ACCORDING TO THEIR HEALTH CARE SYSTEM: ANALYSIS WITHIN THE FRAMEWORK OF THE PTHEMA AML REGISTRY
por: Romero, Monica, et al.
Publicado: (2023)

PB2213: RETROSPECTIVE ANALYSIS OF 45 UNSELECTED PATIENTS WITH HISTIOCYTOSIS CONFIRMS PROGNOSTIC RELEVANCE OF ORGAN INVOLVEMENT: SINGLE‐CENTER EXPERIENCE
por: Yilmaz, Hulya, et al.
Publicado: (2023)

PB2702: POLYPHARMACY IN HEMATOLOGY PRACTISE: A SINGLE CENTER EXPERIENCE
por: Karişmaz, Kadir, et al.
Publicado: (2023)

PB2218: CHILDHOOD MYELPROLIFERATIVE NEOPLASMS; A SINGLE CENTER EXPERIENCE
por: Ghali, Hasanein, et al.
Publicado: (2023)

PB2015: YOUNG ADULTS WITH MULTIPLE MYELOMA – A SINGLE CENTER EXPERIENCE
por: Dos Santos Marques, I., et al.
Publicado: (2022)

PB2047: MOLECULAR DIAGNOSIS OF CONGENITAL ERYTHROCYTOSIS IN A SINGLE HOSPITAL CENTER.
por: Castilla Garcia, L., et al.
Publicado: (2022)

PB2304: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP): A SINGLE-CENTER EXPERIENCE
por: Kammoun, F., et al.
Publicado: (2022)

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS
por: Ciciarello, Marilena, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB1789: RAC1 INHIBITION IS FEASIBLE AND AFFECTS CELL MIGRATION IN A ZEBRAFISH LARVAE MODEL OF AML, INVESTIGATED USING A SOFTWARE TOOL FOR SINGLE-CELL VISUALIZATION
por: Hemsing, Anette Lodvir, et al.
Publicado: (2023)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

PB1788: A SCREENING OF DONATED CHEMICAL PROBES TO IDENTIFY NOVEL THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA (AML) IN CHILDHOOD
por: Laszig, Stephanie, et al.
Publicado: (2023)

PB1772: HIGH SLIT2 LEVELS ARE ASSOCIATED WITH GMP LIKE AML AND TREATMENT WITH RECOMBINANT SLIT2 INHIBITS LEUKEMOGENESIS
por: Simoes, Luise Araujo de Albuquerque, et al.
Publicado: (2023)

PB2242: MANAGEMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA.RETROSPECTIVE STUDY OF A SINGLE CENTER
por: Hortensia-Marioara, I., et al.
Publicado: (2022)

PB2345: MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND SÈZARY SYNDROME: AN ITALIAN SINGLE CENTER EXPERIENCE
por: Simula, Maria Pina, et al.
Publicado: (2023)

PB2609: 14 YEARS OF EXPERIENCE WITH THROMBOPOIETIN RECEPTOR AGONISTS IN A SINGLE CENTER
por: Garcia-Pallarols, Francesc, et al.
Publicado: (2023)

PB1772: IN-VITRO APOPTOTIC EFFECT OF NATURALLY OCCURRING COMPOUNDS, PIPERINE AND ASCORBIC ACID ON ACUTE MYELOID LEUKAEMAI (AML) CELL LINE.
por: Aljohani, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qoao41377bdodi8hku196j10li